Phosphorylation-mediated interaction between human E26 transcription factor 1 and specific protein 1 is required for tumor cell migration

Acta Biochim Biophys Sin (Shanghai). 2022 Oct 25;54(10):1441-1452. doi: 10.3724/abbs.2022148.

Abstract

Transcription factors, human E26 transcription factor 1 (Ets1) and specific protein 1 (Sp1), are known to induce gene expression in tumorigenicity. High Ets1 expression is often associated with colorectal tumorigenesis. In this study, we discover that metastasis and clone formation in SW480 cells mainly depend on the direct interaction between Ets1 and Sp1 instead of high Ets1 expression. The interaction domains are further addressed to be the segment at Sp1(626-708) and the segment at Ets1(244-331). In addition, the phosphorylation inhibition of Ets1 at Tyr283 by either downregulation of Src kinase or Src family inhibitor treatment decreases the interaction between Sp1 and Ets1 and suppresses SW480 migration. Either administration or overexpression of the peptides harboring the interaction segment strongly inhibits the colony formation and migration of SW480 cells. Our findings suggest that the interaction between Ets1 and Sp1 rather than Ets1 alone promotes transformation in SW480 cells and provide new insight into the Ets1 and Sp1 interaction as an antitumour target in SW480 cells.

Keywords: Dasatinib; Ets1; PP2; Sp1; colon cancer; protein interactions.

MeSH terms

  • Cell Line, Tumor
  • Cell Movement*
  • Humans
  • Phosphorylation
  • Proto-Oncogene Protein c-ets-1* / metabolism
  • Sp1 Transcription Factor* / metabolism

Substances

  • ETS1 protein, human
  • SP1 protein, human
  • Proto-Oncogene Protein c-ets-1
  • Sp1 Transcription Factor

Grants and funding

This work was supported by the grants from the Joint Fund of the Department of Education of Guangdong Province (No. 2018KZDXM015), the National Natural Science Foundation of China (No. 31471234) and the Special Funds for the Cultivation of Guangdong College Students′ Scientific and Technological Innovation (“Climbing Program”; No. pdjh2020b0091).